Investigating how RABL6A and PP2A affect neuroendocrine tumors
Official title: Role of RABL6A-PP2A in neuroendocrine tumors
Funded at University of Iowa · NIH-11072006 · Data updated 2026-11-12
This study is looking at how certain proteins affect the growth of pancreatic neuroendocrine tumors, with the hope of finding new treatments that could help patients with these tough-to-treat cancers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project start | May 1, 2021 |
| Project end | April 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $515,955 |
| NIH project number | 5R01CA260200-05 |
| Project ID | NIH-11072006 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with advanced neuroendocrine tumors, particularly those with pancreatic NETs.
✕Less likely to help
Patients with early-stage neuroendocrine tumors or those with other types of cancer may not benefit from this research.
What this research studies
This research focuses on understanding the mechanisms behind neuroendocrine tumors (NETs), which are challenging to treat and often incurable. The study explores the role of a specific pathway involving RABL6A and protein phosphatase 2A (PP2A) in the progression of pancreatic NETs. By examining how RABL6A promotes tumor growth and how PP2A acts as a tumor suppressor, the researchers aim to identify new therapeutic strategies. The use of small molecule activators of PP2A shows promise in reducing tumor cell proliferation and could lead to innovative treatments for patients with advanced NETs.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve outcomes for patients with advanced neuroendocrine tumors.
How similar studies have gone: Other research has shown promise in targeting similar pathways in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
-
University of Iowa
Iowa City, United States Active
Researchers
- Principal investigator: Quelle, Dawn E — University of Iowa
- Study coordinator: Quelle, Dawn E
Related research
Other NIH-funded projects on the same topics.
-
Angiopoietin-2 and Tie2 signals shaping liver metastasis in pancreatic neuroendocrine tumors
A study explores how Angiopoietin-2 and the Tie2 receptor influence the spread of pancreatic neuroendocrine tumors to the liver and how this affects responses to immunotherapy.
-
Enteric glial cell reprogramming and MENIN loss in dpNETs
A study to understand how losing a gene called MENIN in gut-supporting glial cells might turn them into neuroendocrine tumor cells in people with MEN1.
-
Targeting CXCR4 and redox metabolism to treat lung neuroendocrine cancers with targeted alpha therapy
Aims to develop a new alpha-particle therapy approach for hard-to-treat lung neuroendocrine tumors by attacking CXCR4 and redox pathways.
-
Optimizing Theranostic Dosimetry and Kidney Biomarkers for Alpha-Emitter Radioligand Therapy in Neuroendocrine Tumors
This project tests a new targeted radiotherapy approach for neuroendocrine tumors to maximize tumor response while protecting kidneys.
-
SSTR2 imaging to guide pituitary tumor radiotherapy and planning
This project tests a PET/MRI imaging approach to map somatostatin receptor 2 in pituitary neuroendocrine tumors to help tailor radiation therapy for better tumor control.
-
Chromatin biomarkers linked to prognosis in non-functional pancreatic neuroendocrine tumors
A study exploring chromatin-related biomarkers to better predict which non-functional pancreatic neuroendocrine tumors may behave aggressively.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.